Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus with reduced-exposure cyclosporine or tacrolimus in pediatric liver transplant recipients
2011-003069-14Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2012
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of everolimus, cyclosporine and tacrolimus in liver transplant, sponsored by Novartis. Started Apr 2012; status: completed.
02
Drugs
everolimuscyclosporinetacrolimus
03
Conditions
liver transplant
Beyond the preview
Go deeper on 2011-003069-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003069-14.